E. coli Infections
Also known as: Escherichia coli
Methodology & AI Transparency ⓘ
E. coli Infections Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: E.
- 2 Real-world patient consensus: Synonyms for E. coli Infections (B37.4): Escherichia coli (Infections & Antivirals).
- 3 Typical cash cost range: Workup highlights for E. coli Infections (B37.4): antimicrobial stewardship (narrow-spectrum in E. coli Infections (B37.4: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Key Infections & Antivirals biomarkers for E. coli Infections (B37.4): Complete Blood Count in E. coli Infections (B37.4: (WBC & Differential)) & C-Reactive Protein / in E. coli Infections (B37.4: Procalcitonin) (Resolution to baseline (B37.4)).
Ask our AI Specialists anything about E. coli Infections
What Is E. coli Infections?
E. coli is the name of a type of bacteria that lives in your intestines. Most types of E. coli are harmless. However, some types can make you sick and cause diarrhea . One type causes travelers' diarrhea. The worst type of E. coli causes bloody diarrhea, and can sometimes cause kidney failure and even death. These problems are most likely to occur in children and in adults with weak immune systems. You can get E. coli infections by eating foods containing the bacteria. Symptoms of infection include: Nausea or vomiting Severe abdominal cramps Watery or very bloody diarrhea Fatigue Fever To help avoid food poisoning and prevent infection, handle food safely .
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of E. coli Infections (B37.4, Infections & Antivirals) reflects pathogen-associated molecular pattern in E. coli Infections (B37.4: (PAMP) innate immune). Cross-referenced with NIH MeSH (Escherichia coli Infections), longitudinal control is benchmarked via Complete Blood Count in E. coli Infections (B37.4: (WBC & Differential)).
Common Symptoms & Clinical Signs
- • Nausea or vomiting
- • Severe abdominal cramps
- • Presentation of E. coli Infections (B37.4): acute fever, chills, in E. coli Infections (B37.4: malaise, and myalgias)
- • Secondary E. coli Infections clinical sign: sore throat, productive in E. coli Infections (B37.4: cough, sinus/ear pain,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
E. coli Infections Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B37.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in E. coli Infections (B37.4: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B37.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in E. coli Infections (B37.4: Procalcitonin) | Resolution to baseline (B37.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in E. coli Infections (B37.4: Culture & Sensitivity) | Pathogen clearance / negative test (B37.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for E. coli Infections
Treatment selection for E. coli Infections depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (E. coli Infections)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with: What a 1,212-Participant Study Found Olgotrelvir as a single-agent treatment significantly improved symptom recovery. NEJM evidence • 2024-06-15 • Phase III Randomized Trial | N = 1,212 | 96/100 | PMID 38804790 ↗ |
| New Insights on Benefits and safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor: What a 1,139-Participant Study Found Tofacitinib was efficacious in patients with UC regardless of prior TNFi failure status. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2022-03-15 • Phase III Randomized Trial | N = 1,139 | 96/100 | PMID 33684552 ↗ |
| Check Your Medicine Cabinet: Family Farmstead Dairy Announces Recall of Raw Mild Cheddar Cheese Due to Potential E. c WORCESTER, NY, October 15, 2026 - Family Farmstead Dairy of Worcester, NY is recalling specific lot of cheddar cheese because it may be contaminated with Escherichia coli O157:H7 bacteria (E. Coli O157:H7). E. coli O157:H7 causes a diarrheal illness often with FDA Drug Recalls • 2026-10-15 • FDA Recall | Multi-cohort | 95/100 | PMID FDA_RECALLS-2412744266 ↗ |
| New Insights on Glycolipid and Hormonal Profiles in Young Men with Early-Onset Androgenetic hair: What a 1,009-Participant Study Found The acknowledgement of this syndrome would be of importance to prevent the long-term consequences on health in the affected men. Scientific reports • 2017-08-10 • Meta-Analysis | N = 1,009 | 94/100 | PMID 28798373 ↗ |
| New Insights on Long-term safety and real-world benefits of filgotinib for the treatment of: What a 250-Participant Study Found Filgotinib induced and maintained symptomatic full symptom relief and improved HRQoL over 4 years. Alimentary pharmacology & therapeutics • 2024-09-15 • Phase III Randomized Trial | N = 250 | 93/100 | PMID 39086130 ↗ |
E. coli Infections Patient Community & “People Like Me” Threads
Filter E. coli Infections community threads and patient logs by age, biological sex, dosage, and treatment duration.